Breakthroughs in Immunotherapy functions by measuring cytokine and cytolytic protein secretion. Representing a promising new class of therapeutics, bispecific T-cell engagers (BiTEs) harness the power of the adaptive immune response by enhancing the ability of CTLs to specifically recognize and eliminate tumors. CD19-BiTEs are designed to bind CD3 on CTLs as well as CD19 on cells of B-cell lineage, simultaneously activating T cells and bringing them in close proximity to the B cells, thus enhancing CTL effector function against various B-cell-derived tumors. Here, the capability of CD19-BiTEs to enhance the cytotoxic effects of T lymphocytes on a B-cell lymphoma cell line (Daudi cells), was evaluated using two distinct assays. Target cell death was monitored using an real-time cell analysis impedance assay while secretion of cytokines and cytolytic proteins was qualified in a beadbased multiplex flow cytometry assay to evaluate the potency of the over multifunctional T-cell response. Enhancing T-cell-mediated target cell killing To demonstrate T-cell-mediated target-cell cytotoxicity on the xCELLigence platform, human 35 | GENengnews.com Figure 1. Target cell death was monitored using the xCELLigence RTCA impedance assay while secretion of cytokines and cytolytic proteins was qualified in a bead-based multiplex assay on the NovoCyte flow cytometer to evaluate the T-cell response.http://www.GENengnews.com